Rowan Paul: MSCs Show Strongest Pain Reduction in Regenerative Medicine Approaches
Rowan Paul, Sports Medicine and Interventional Regenerative Orthobiologics Physician at RegenCore, shared on LinkedIn:
”My key takeaway is that MSCs showed the strongest pain reduction. Nice to see this born out in the peer reviewed literature. Happy to be doing Prospective Clinical Trial research.
PRP
Efficacy:
- Best for acute injuries and tendon repair-patellar tendinopathy, knee OA, lateral epicondylitis
- Superior to corticosteroids and HA
- Limited success in chronic conditions:
Limitations
- Hard to generalize across all indications. be precise in formulation of your PRP depending on structure, patient, and goals
- Inconsistent preparation methods
- Optimal: LP- PRP, weekly × 3 weeks
- Requires 10-12 billion cumulative over course:
Mechanism
- VEGF, PDGF, TGF-β release stimulates angiogenesis and matrix synthesis[1]
Mesenchymal Stem Cells (MSCs)
Efficacy:
- Highest pain reduction among all modalities
- Cartilage regeneration in early OA
- Sustained improvements at 12-24 months
Mechanism
- Immunomodulation, reduced inflammation, M2 macrophage polarization
Major Barriers:
- High costs and ethical concerns
- Experimental
- Symptomatic relief insufficient to justify costs on a system level
Peptide-Based Therapies
- Moderate improvements; promising for infection control and wound healing
- Limited evidence (10 studies)
- Needs optimization of dosing, delivery, safety
Biomimetic Materials
- Scaffolds, Autologous Protein Solutions, PRF.
- Lowest efficacy in meta-analysis[1]
Clinical Practice Insights
Standardization Challenges:
- Variable methods and heterogeneous formulations= inconsistent results
- Insufficient reporting limits evidence synthesis
- This is a particular interest of mine and we need more research
Evidence Characterization:
- ‘Symptom-modifying’ vs ‘structure-modifying’—improve pain/function but limited true regeneration
- Short/mid-term results noticeable; long-term stability undetermined
- Need long-term follow-up to see structural changes
Precision Medicine Need:
- Must identify potency markers to match treatments to tissues/pathologies
- Improved mechanistic understanding enables precision approaches
Market Landscape
- 51.5% of publications focus on PRP, 30.8% bone marrow, 15.2% adipose-derived cells. We need more MSC research as well as scaffolding research and this takes investment and funding.”
Title: Advancements in Regenerative Therapies for Orthopedics: A Comprehensive Review of Platelet-Rich Plasma, Mesenchymal Stem Cells, Peptide Therapies, and Biomimetic Applications
Authors: Andrew J Goulian, Brielle Goldstein, Maarouf A Saad
Read the Full Article on National Library of Medicine.
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 24, 2026, 17:12Ron DePinho: CRISPR Progress in Cellular Immunotherapy
-
Mar 24, 2026, 17:12Martine Gilard։ Women’s Heart Health as a National Priority
-
Mar 24, 2026, 17:11Erik Nelson։ Blood Vessels – The Silent System That Determines How You Age
-
Mar 24, 2026, 17:10Anthony Yazbeck: Why the Hemolysin Test Matters More Than You Think
-
Mar 24, 2026, 17:09Marcos Gamboa Chele: Are We Asking for Too Many Thrombophilia Panels?
-
Mar 24, 2026, 17:06Anita Brikman: PPTA Explores India’s Growing Plasma-Derived Medicines Industry
-
Mar 24, 2026, 17:01Victor Canata: Is Embolectomy the Best Treatment for Pulmonary Thromboembolism?
-
Mar 24, 2026, 16:57Hossam Qassem: The Stepwise Investigation Framework for ICU Hemoglobin Drop
-
Mar 24, 2026, 16:56Alan Nurden: Targeting Splice Site Variants in Alport Syndrome with Antisense Therapy